{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T21:18:19Z","timestamp":1776374299806,"version":"3.51.2"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Centre of Excellence for Gastrointestinal Inflammation and Immunity Research"},{"name":"University of Alberta Department of Medicine"},{"name":"University of Alberta Gastroenterology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s10620-020-06381-5","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T10:03:00Z","timestamp":1591956180000},"page":"1639-1649","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Fecal Calprotectin May Predict Adverse Pregnancy-Related Outcomes in Patients with Inflammatory Bowel Disease"],"prefix":"10.1007","volume":"66","author":[{"given":"Parul","family":"Tandon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Hitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsy","family":"Ambrosio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Levinus","family":"Dieleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan","family":"Halloran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Kroeker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4524-9403","authenticated-orcid":false,"given":"Vivian M.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"key":"6381_CR1","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nchembio.1891","volume":"11","author":"TG Nakashige","year":"2015","unstructured":"Nakashige TG, Zhang B, Krebs C, et al. Human calprotectin is an iron-sequestering host-defense protein. Nat Chem Biol. 2015;11:765\u2013771.","journal-title":"Nat Chem Biol"},{"key":"6381_CR2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1572-0241.2007.01126.x","volume":"102","author":"AC von Roon","year":"2007","unstructured":"von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007;102:803\u2013813.","journal-title":"Am J Gastroenterol"},{"key":"6381_CR3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ibd.20275","volume":"14","author":"AM Schoepfer","year":"2008","unstructured":"Schoepfer AM, Trummler M, Seeholzer P, et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis. 2008;14:32\u201339.","journal-title":"Inflamm Bowel Dis"},{"key":"6381_CR4","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/MIB.0b013e3182810066","volume":"19","author":"AM Schoepfer","year":"2013","unstructured":"Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013;19:332\u2013341.","journal-title":"Inflamm Bowel Dis"},{"key":"6381_CR5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ibd.20312","volume":"14","author":"T Sipponen","year":"2008","unstructured":"Sipponen T, Savilahti E, Kolho K-L, et al. Crohn\u2019s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn\u2019s disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14:40\u201346.","journal-title":"Inflamm Bowel Dis"},{"key":"6381_CR6","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.gastro.2006.12.038","volume":"132","author":"G D\u2019Haens","year":"2007","unstructured":"D\u2019Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763\u2013786.","journal-title":"Gastroenterology"},{"key":"6381_CR7","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/MIB.0000000000001082","volume":"23","author":"A Heida","year":"2017","unstructured":"Heida A, Park KT, van Rheenen PF. Clinical utility of fecal calprotectin monitoring in asymptomatic patients with inflammatory bowel disease: a systematic review and practical guide. Inflamm Bowel Dis. 2017;23:894\u2013902.","journal-title":"Inflamm Bowel Dis"},{"key":"6381_CR8","first-page":"33","volume":"9","author":"P Molander","year":"2015","unstructured":"Molander P, Farkkila M, Ristimaki A, et al. Does fecal calprotectin predict short-term relapse after stopping TNFalpha-blocking agents in inflammatory bowel disease patients in deep remission? J Crohn\u2019s Colitis. 2015;9:33\u201340.","journal-title":"J Crohn\u2019s Colitis"},{"key":"6381_CR9","doi-asserted-by":"crossref","first-page":"175628481878557","DOI":"10.1177\/1756284818785571","volume":"11","author":"YS Tham","year":"2018","unstructured":"Tham YS, Yung DE, Fay S, et al. Fecal calprotectin for detection of postoperative endoscopic recurrence in Crohn\u2019s disease: Systematic review and meta-analysis. Ther Adv Gastroenterol.  2018;11:1756284818785571","journal-title":"Ther Adv Gastroenterol"},{"key":"6381_CR10","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1053\/j.gastro.2015.01.026","volume":"148","author":"EK Wright","year":"2015","unstructured":"Wright EK, Kamm MA, De Cruz P, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn\u2019s disease after surgery. Gastroenterology. 2015;148:938\u2013947.","journal-title":"Gastroenterology"},{"key":"6381_CR11","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/MCG.0000000000001244","volume":"53","author":"P Tandon","year":"2019","unstructured":"Tandon P, Leung K, Yusuf A, et al. Noninvasive methods for assessing inflammatory bowel disease activity in pregnancy: a systematic review. J Clin Gastroenterol. 2019;53:574\u2013581.","journal-title":"J Clin Gastroenterol"},{"key":"6381_CR12","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/MIB.0000000000001102","volume":"23","author":"H Kammerlander","year":"2017","unstructured":"Kammerlander H, Nielsen J, Kjeldsen J, et al. The effect of disease activity on birth outcomes in a nationwide cohort of women with moderate to severe inflammatory bowel disease. Inflamm Bowel Dis. 2017;23:1011\u20131018.","journal-title":"Inflamm Bowel Dis"},{"key":"6381_CR13","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1097\/MIB.0000000000001136","volume":"23","author":"M Julsgaard","year":"2017","unstructured":"Julsgaard M, Hvas CL, Gearry RB, et al. Fecal calprotectin is not affected by pregnancy: clinical implications for the management of pregnant patients with inflammatory bowel disease. Inflamm Bowel Dis. 2017;23:1240\u20131246.","journal-title":"Inflamm Bowel Dis"},{"key":"6381_CR14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.5152\/tjg.2017.16711","volume":"28","author":"A Balint","year":"2017","unstructured":"Balint A, Berenyi A, Farkas K, et al. Pregnancy does not affect fecal calprotectin concentration in healthy women. Turk J Gastroenterol. 2017;28:171\u2013175.","journal-title":"Turk J Gastroenterol"},{"key":"6381_CR15","doi-asserted-by":"publisher","DOI":"10.7754\/clin.lab.2019.190104","author":"T Fall","year":"2019","unstructured":"Fall T, Hedman A, Pershagen G, et al. Reference intervals for fecal calprotectin in pregnant women using a particle enhanced turbidimetric assay. Clin Lab. 2019. https:\/\/doi.org\/10.7754\/clin.lab.2019.190104.","journal-title":"Clin Lab."},{"key":"6381_CR16","doi-asserted-by":"crossref","first-page":"S\u2013452","DOI":"10.1016\/S0016-5085(15)31526-2","volume":"148","author":"V Huang","year":"2015","unstructured":"Huang V, Bal J, Foshaug RR, et al. Su1255 fecal calprotectin is elevated with clinical disease activity during pregnancy in women with inflammatory bowel disease. Gastroenterology. 2015;148:S\u2013452.","journal-title":"Gastroenterology"},{"key":"6381_CR17","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/ibd\/izx055","volume":"24","author":"H Kammerlander","year":"2018","unstructured":"Kammerlander H, Nielsen J, Kjeldsen J, et al. Fecal calprotectin during pregnancy in women with moderate-severe inflammatory bowel disease. Inflamm Bowel Dis. 2018;24:839\u2013848.","journal-title":"Inflamm Bowel Dis"},{"key":"6381_CR18","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1002\/ibd.22917","volume":"18","author":"G D\u2019Haens","year":"2012","unstructured":"D\u2019Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218\u20132224.","journal-title":"Inflamm Bowel Dis"},{"key":"6381_CR19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/ecco-jcc\/jjv006","volume":"9","author":"YPY Leung","year":"2015","unstructured":"Leung YPY, Kaplan GG, Coward S, et al. Intrapartum corticosteroid use significantly increases the risk of gestational diabetes in women with inflammatory bowel disease. J Crohn\u2019s Colitis. 2015;9:223\u2013230.","journal-title":"J Crohn\u2019s Colitis"},{"key":"6381_CR20","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/gut.2006.108324","volume":"56","author":"J Cornish","year":"2007","unstructured":"Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut. 2007;56:830\u2013837.","journal-title":"Gut"},{"key":"6381_CR21","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/ibd\/izy081","volume":"24","author":"B Koslowsky","year":"2018","unstructured":"Koslowsky B, Grisaru-Granovsky S, Livovsky DM, et al. Pregnancy-onset inflammatory bowel disease: a subtle diagnosis. Inflamm Bowel Dis. 2018;24:1826\u20131832.","journal-title":"Inflamm Bowel Dis"},{"key":"6381_CR22","first-page":"S\u2013844","volume":"156","author":"P Tandon","year":"2019","unstructured":"Tandon P, Ambrosio L, Yusuf A, et al. The modified Harvey-Bradshaw index and partial Mayo score do not predict active inflammatory bowel disease during pregnancy: a prospective analysis. Gastroenterology. 2019;156:S\u2013844.","journal-title":"Gastroenterology"},{"key":"6381_CR23","doi-asserted-by":"crossref","first-page":"e287","DOI":"10.1017\/S0950268819001675","volume":"147","author":"W Alfouzan","year":"2019","unstructured":"Alfouzan W, Fadhli Al M, Abdo N, et al. Surgical site infection following cesarean section in a general hospital in Kuwait: trends and risk factors. Epidemiol Infect. 2019;147:e287.","journal-title":"Epidemiol Infect"},{"key":"6381_CR24","doi-asserted-by":"crossref","first-page":"170","DOI":"10.11124\/JBISRIR-2017-003587","volume":"17","author":"E Rydahl","year":"2019","unstructured":"Rydahl E, Eriksen L, Juhl M. Effects of induction of labor prior to post-term in low-risk pregnancies: a systematic review. JBI Database Syst Rev Implement Rep. 2019;17:170\u2013208.","journal-title":"JBI Database Syst Rev Implement Rep"},{"key":"6381_CR25","first-page":"25","volume":"56","author":"JH Vardo","year":"2011","unstructured":"Vardo JH, Thornburg LL, Glantz JC. Maternal and neonatal morbidity among nulliparous women undergoing elective induction of labor. J Reprod Med. 2011;56:25\u201330.","journal-title":"J Reprod Med"},{"key":"6381_CR26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00404-019-05208-7","volume":"300","author":"Y Li","year":"2019","unstructured":"Li Y, Zhang C, Zhang D. Cesarean section and the risk of neonatal respiratory distress syndrome: a meta-analysis. Arch Gynecol Obstet. 2019;300:503\u2013517.","journal-title":"Arch Gynecol Obstet"},{"key":"6381_CR27","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1503\/cmaj.060870","volume":"176","author":"S Liu","year":"2007","unstructured":"Liu S, Liston RM, Joseph KS, et al. Maternal mortality and severe morbidity associated with low-risk planned cesarean delivery versus planned vaginal delivery at term. CMAJ. 2007;176:455\u2013460.","journal-title":"CMAJ"},{"key":"6381_CR28","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/ajg.2016.254","volume":"111","author":"A de Lima-Karagiannis","year":"2016","unstructured":"de Lima-Karagiannis A, Zelinkova-Detkova Z, van der Woude CJ. The effects of active IBD during pregnancy in the era of novel IBD therapies. Am J Gastroenterol. 2016;111:1305\u20131312.","journal-title":"Am J Gastroenterol"},{"key":"6381_CR29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/ibd\/izz110","volume":"26","author":"M Julsgaard","year":"2020","unstructured":"Julsgaard M, Hvas CL, Geary RB, et al. Anti-TNF therapy in pregnancy women with inflammatory bowel disease: effects of therapeutic strategies on disease behavior and birth outcomes. Inflamm Bowel Dis. 2020;26:93\u2013102.","journal-title":"Inflamm Bowel Dis"},{"key":"6381_CR30","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/ajg.2017.501","volume":"113","author":"M Chaparro","year":"2018","unstructured":"Chaparro M, Verreth A, Lobaton T, et al. Long-term safety of in utero exposure to anti-TNFalpha drugs for the treatment of inflammatory bowel disease: results from the multicenter European TEDDY study. Am J Gastroenterol. 2018;113:396\u2013403.","journal-title":"Am J Gastroenterol"},{"key":"6381_CR31","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10735-012-9410-6","volume":"43","author":"SM Almasry","year":"2012","unstructured":"Almasry SM, Eldomiaty MA, Elfayomy AK, et al. Expression pattern of tumor necrosis factor alpha in placentae of idiopathic fetal growth restriction. J Mol Histol. 2012;43:253\u2013261.","journal-title":"J Mol Histol"},{"key":"6381_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2015.00089","volume":"6","author":"KG Pringle","year":"2015","unstructured":"Pringle KG, Rae K, Weatherall L, et al. Effects of maternal inflammation and exposure to cigarette smoke on birth weight and delivery of preterm babies in a cohort of indigenous Australian women. Front Immunol. 2015;6:1\u20137.","journal-title":"Front Immunol"},{"key":"6381_CR33","doi-asserted-by":"crossref","first-page":"S650","DOI":"10.1016\/j.ajog.2018.11.1036","volume":"220","author":"MA Kennelly","year":"2019","unstructured":"Kennelly MA, Ainscough K, Phillips C, et al. Maternal inflammation: potential mediators and effects on pregnancy outcomes. AJOG. 2019;220:S650\u2013S651.","journal-title":"AJOG"},{"key":"6381_CR34","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jama.2010.78","volume":"303","author":"DO Mook-Kanamori","year":"2010","unstructured":"Mook-Kanamori DO, Steegers EA, Ellers PH, et al. Risk factors and outcomes associated with first-trimester fetal growth restriction. JAMA. 2010;303:527\u2013534.","journal-title":"JAMA"},{"key":"6381_CR35","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","volume":"390","author":"J-F Colombel","year":"2018","unstructured":"Colombel J-F, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2018;390:2779\u20132789.","journal-title":"Lancet"},{"key":"6381_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-020-06122-8","author":"MS Ko","year":"2020","unstructured":"Ko MS, Rudrapatna VA, Avila P, et al. Safety of flexible sigmoidoscopy in pregnant patients with known or suspected inflammatory bowel disease. Dig Dis Sci. 2020. https:\/\/doi.org\/10.1007\/s10620-020-06122-8.","journal-title":"Dig Dis Sci"},{"key":"6381_CR37","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/ecco-jcc\/jjv079","volume":"9","author":"A de Lima","year":"2015","unstructured":"de Lima A, Zelinkova Z, van der Woude CJ. A prospective study of the safety of lower gastrointestinal endoscopy during pregnancy in patients with inflammatory bowel disease. J Crohn\u2019s Colitis. 2015;9:519\u2013524.","journal-title":"J Crohn\u2019s Colitis"},{"key":"6381_CR38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1258\/acb.2012.011272","volume":"50","author":"SJ Whitehead","year":"2013","unstructured":"Whitehead SJ, French J, Brookes MJ, et al. Between-assay variability of faecal calprotectin enzyme-linked immunosorbent assay kits. Ann Clin Biochem. 2013;50:53\u201361.","journal-title":"Ann Clin Biochem"},{"key":"6381_CR39","doi-asserted-by":"crossref","first-page":"e0214751","DOI":"10.1371\/journal.pone.0214751","volume":"14","author":"S-M Haisma","year":"2019","unstructured":"Haisma S-M, Galaurchi A, Almahwzi S, et al. Head-to-head comparison of three stool calprotectin tests for home use. PloS One. 2019;14:e0214751.","journal-title":"PloS One"},{"key":"6381_CR40","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1515\/cclm-2016-1012","volume":"55","author":"M Oyaert","year":"2017","unstructured":"Oyaert M, Boel A, Jacobs J, et al. Analytical performance and diagnostic accuracy of six different faecal calprotectin assays in inflammatory bowel disease. Clin Chem Lab Med. 2017;55:1564\u20131573.","journal-title":"Clin Chem Lab Med"},{"key":"6381_CR41","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1515\/cclm-2018-0134","volume":"56","author":"A Padoan","year":"2018","unstructured":"Padoan A, D\u2019Inca R, Scapellato ML, et al. Improving IBD diagnosis and monitoring by understanding preanalytical, analytical and biological fecal calprotectin variability. Clin Chem Lab Med. 2018;56:1926\u20131935.","journal-title":"Clin Chem Lab Med"},{"key":"6381_CR42","first-page":"26","volume":"9","author":"A Lasson","year":"2015","unstructured":"Lasson A, Stotzer P-O, Ohman L, et al. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohn\u2019s Colitis. 2015;9:26\u201332.","journal-title":"J Crohn\u2019s Colitis"},{"key":"6381_CR43","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MCG.0000000000000776","volume":"52","author":"L Du","year":"2018","unstructured":"Du L, Foshaug R, Huang VW, et al. Within-stool and within-day sample variability of fecal calprotectin in patients with inflammatory bowel disease: a prospective observational study. J Clin Gastroenterol. 2018;52:235\u2013240.","journal-title":"J Clin Gastroenterol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06381-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-020-06381-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06381-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T23:05:03Z","timestamp":1623452703000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-020-06381-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["6381"],"URL":"https:\/\/doi.org\/10.1007\/s10620-020-06381-5","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,12]]},"assertion":[{"value":"18 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"All study authors have no personal conflicts to declare with respect to this particular study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}